At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19

• Status: Completed
• Trial end date: 2021-04-18
• Target enrollment: 0
• Participant gender: All

Summary

This is an open-label, pragmatic, single-dose study using matched controls in participants with mild to moderate COVID-19. Participants will track for developing symptoms while at home and upon reporting of symptoms will test for COVID-19. If positive for COVID-19, a one-time at-home infusion of Bamlanivimab (LY3819253) will be provided by Optum Infusion. Participants will then track for 28 days to assess for any additional medical care needed or if hospitalization was required.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Daniel Griffin; Daniel Griffin, MD PhD
• Collaborators: Eli Lilly and Company; Optum, Inc.

Criteria

Inclusion Criteria:

• UnitedHealthcare member

• confirmed COVID-19 positive

• located in an area where Bamlanivimab (LY3819253) is available for infusion

Exclusion Criteria:

• current (from first symptom report) hospitalization for COVID-19

• prior administration of Bamlanivimab or other COVID-19 therapies

• previous COVID-19 diagnosis

• prior receipt of a COVID-19 vaccine

• not authorized for patient use per the EUA